临床试验/NCT05462470

NCT05462470已完成不适用

Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis

Fudan University0 个研究点目标入组 255 人开始时间: 2008年1月1日最近更新: 2022年7月19日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Fudan University
入组人数: 255
主要终点: overall survival

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

For patients with initially unresectable colorectal liver metastasis (IU-CRLM) receiving effective conversion therapy, disease relapse after conversion hepatectomy is common due to the extensive tumor load. Yet, few studies have focused on the assessment and management of relapse after conversion hepatectomy for IU-CRLM. This study aimed to investigate the impact of surgical management for relapse after conversion hepatectomy in IU-CRLM.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•initially unresectable colorectal liver metastasis (IU-CRLM)
•received conversion therapy
•underwent conversion hepatectomy

排除标准

•the histologic type of CRLM was not called adenocarcinoma
•uncontrollable extrahepatic metastases, such as peritoneal, bone, brain metastasis
•history of previous hepatectomy
•the primary tumor was not resected or palliative resection
•R1 or R2 liver resection

结局指标

主要结局

overall survival

时间窗: 5 years

Overall survival after the first resection of liver metastatic lesions

次要结局

first relapse free survival(5 years)
second relapse free survival(5 years)
Severe complication rate after resection of primary and metastatic lesions(30 days after surgery)

研究者

发起方

Fudan University

申办方类型

Other

责任方

Principal Investigator

主要研究者

Xu jianmin

Deputy director of the department of general surgery

Fudan University

相似试验

招募中

1 期

Anti-CEA CAR-T Cells to Treat Colorectal Liver MetastasesMetastatic Liver CancerColorectal Cancer

NCT05240950Changhai Hospital18

已完成

2 期

FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-typeMetastatic Colorectal Cancer

NCT02350530Sun Yat-sen University138

招募中

不适用

Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver MetastasesLiver MetastasesColorectal Cancer

NCT02864485University Health Network, Toronto20

招募中

3 期

Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNALiver MetastasesCirculating Tumor CellCancer, Therapy-RelatedColorectal Cancer

NCT05797077Sixth Affiliated Hospital, Sun Yat-sen University346

招募中

不适用

Follow-up after surgery for liver metastases: the FUTURE-mets study

NL-OMON26930Prof. Dr. C. Verhoef, Erasmus MC Cancer Institute138